PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: A prospective multicenter clinical study

Journal of Urology

Volumn 190, Issue 1, 2013, Pages 64-69

  Gittelman, Marc C ^a   Hertzman, Bernard ^c   Bailen, James ^d   Williams, Thomas ^b   Koziol, Isaac ^e   Henderson, Ralph Jonathan ^f   Efros, Mitchell ^g   Bidair, Mohamed ^h   Ward, John F ⁱ  

^a 21ST CENTURY ONCOLOGY   (United States)

^b Florida Cancer Specialists   (United States)

^c Tri State Urologic Services P S C Inc   (United States)

^d Metropolitan Urology   (United States)

^e Virginia Urology   (United States)

^f Regional Urology   (United States)

^g Accumed Research Associates   (United States)

^h San Diego Arthritis Medical Clinic   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

Author keywords

biopsy; prognosis; prostate; prostate cancer antigen 3, human; prostatic neoplasms

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; REPEAT PROSTATE BIOPSY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUBE; URINALYSIS;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; CONFIDENCE INTERVALS; DIGITAL RECTAL EXAMINATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE-GUIDED BIOPSY; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84878853813     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.02.018     Document Type: Article

References (29)

1. American Cancer Society Cancer Facts and Figures 2012 American Cancer Society Atlanta
2. V.A. Moyer U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120
3. W.J. Catalona, J.P. Richie, F.R. Ahmann Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men J Urol 151 1994 1283
4. R.L. Grubb, P.F. Pinsky, R.T. Greenlee Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial BJU Int 102 2008 1524
5. F.H. Schröder, J. Hugosson, M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320
6. B. Djavan, V. Ravery, A. Zlotta Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679
7. K.A. Roehl, J.A. Antenor, W.J. Catalona Serial biopsy results in prostate cancer screening study J Urol 167 2002 2435
8. M.J. Resnick, D.J. Lee, L. Magerfleisch Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer Urology 77 2011 548
9. R. Raaijmakers, W.J. Kirkels, M.J. Roobol Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program Urology 60 2002 826
10. J. Raja, N. Ramachandran, G. Munneke Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer Clin Radiol 61 2006 142
11. R.K. Nam, R. Saskin, Y. Lee Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy J Urol 183 2010 963
12. M.J. Bussemakers, A. van Bokhoven, G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975
13. J.B. de Kok, G.W. Verhaegh, R.W. Roelofs DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695
14. D. Hessels, J.M. Klein Gunnewiek, I. van Oort DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8
15. L.S. Marks, Y. Fradet, I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532
16. I.L. Deras, S.M. Aubin, A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587
17. A. Haese, A. de la Taille, H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081
18. M.J. Roobol, F.H. Schröder, P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475
19. S.M. Aubin, J. Reid, M.J. Sarno PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial J Urol 184 2010 1947
20. H. Nakanishi, J. Groskopf, H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804
21. M. Auprich, F.K. Chun, J.F. Ward Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol 59 2011 96
22. G. Ploussard, X. Durand, E. Xylinas Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance Eur Urol 59 2011 422
23. A.K. Wu, A.C. Reese, M.R. Cooperberg Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer Prostate Cancer Prostatic Dis 15 2012 100
24. J. Groskopf, S.M. Aubin, I.L. Deras APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089
25. E.R. DeLong, D.M. DeLong, D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837
26. E.J. Whitman, J. Groskopf, A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975
27. V. Vlaeminck-Guillem, M. Devonec, M. Colombel Urinary PCA3 score predicts prostate cancer multifocality J Urol 185 2011 1234
28. M.P. van Gils, D. Hessels, C.A. Hulsbergen-van de Kaa Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results Prostate 68 2008 1215
29. D. Hessels, M.P. van Gils, O. van Hooij Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer Prostate 70 2010 10